Reprieve Cardiovascular Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Employees
  • 28

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $61M

  • Investors
  • 11

Reprieve Cardiovascular General Information

Description

Developer of an intelligent decongestion management technology designed to advance heart failure treatment. The company uses real-time physiological monitoring, automated therapy recommendations, precise diuretic administration, intelligent decongestion management, personalized fluid management, and integrated clinical workflows, enabling physicians to safely accelerate fluid removal for heart failure patients.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 459 Fortune Boulevard
  • Milford, MA 01757
  • United States
+1 (617)
Primary Industry
Biotechnology
Other Industries
Therapeutic Devices
Other Healthcare Technology Systems
Monitoring Equipment
Corporate Office
  • 459 Fortune Boulevard
  • Milford, MA 01757
  • United States
+1 (617)

Reprieve Cardiovascular Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Reprieve Cardiovascular Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC (Series B) 17-Sep-2025 $61M Completed Clinical Trials - Phase 2
2. Later Stage VC (Series A1) 17-Nov-2023 Completed Clinical Trials - Phase 2
1. Early Stage VC (Series A) 07-Jun-2022 $30M $30M Completed Clinical Trials - Phase 1
To view Reprieve Cardiovascular’s complete valuation and funding history, request access »

Reprieve Cardiovascular Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B-3
Series B-2
Series B-1
Series A-1 12,050,001 $0.000010 $1 $1 1x $1 7.44%
Series A 33,310,000 $0.000010 $1 $1 1x $1 20.57%
To view Reprieve Cardiovascular’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Reprieve Cardiovascular Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of an intelligent decongestion management technology designed to advance heart failure treatment. The company
Biotechnology
Milford, MA
28 As of 2025

San Diego, CA
 

Raleigh, NC
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Reprieve Cardiovascular Competitors (14)

One of Reprieve Cardiovascular’s 14 competitors is DexCom, a Formerly VC-backed company based in San Diego, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
DexCom Formerly VC-backed San Diego, CA
Sensible Medical Venture Capital-Backed Raleigh, NC
Cardiac Dimensions Venture Capital-Backed Kirkland, WA
Spine Wave Venture Capital-Backed Shelton, CT
BrioHealth Solutions Venture Capital-Backed Suzhou, China
You’re viewing 5 of 14 competitors. Get the full list »

Reprieve Cardiovascular Patents

Reprieve Cardiovascular Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026128850-A1 Improved fluid therapy systems, and associated devices and methods Pending 12-Dec-2024
US-12582773-B2 Urine output sensing without use of an indwelling catheter, and associated systems, devices, and methods Active 16-Feb-2024
US-20250262380-A1 Urine output sensing without use of an indwelling catheter, and associated systems, devices, and methods Active 16-Feb-2024
WO-2025175244-A1 Urine output sensing without use of an indwelling catheter, and associated systems, devices, and methods Pending 16-Feb-2024
US-12471842-B2 Fluid therapy based on adjusted urine output rate, and associated systems, devices, and methods Active 12-Sep-2023 A61B5/4839
To view Reprieve Cardiovascular’s complete patent history, request access »

Reprieve Cardiovascular Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Reprieve Cardiovascular Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds
Cadence Capital Corporation Minority
Genesis Capital (Investment Banks) Investment Bank Minority
Santen Ventures Corporate Venture Capital Minority
UNC Health Ventures Corporate Venture Capital Minority
Abiomed Corporation Minority
You’re viewing 5 of 11 investors. Get the full list »

Reprieve Cardiovascular FAQs

  • When was Reprieve Cardiovascular founded?

    Reprieve Cardiovascular was founded in 2018.

  • Where is Reprieve Cardiovascular headquartered?

    Reprieve Cardiovascular is headquartered in Milford, MA.

  • What is the size of Reprieve Cardiovascular?

    Reprieve Cardiovascular has 28 total employees.

  • What industry is Reprieve Cardiovascular in?

    Reprieve Cardiovascular’s primary industry is Biotechnology.

  • Is Reprieve Cardiovascular a private or public company?

    Reprieve Cardiovascular is a Private company.

  • What is the current valuation of Reprieve Cardiovascular?

    The current valuation of Reprieve Cardiovascular is .

  • What is Reprieve Cardiovascular’s current revenue?

    The current revenue for Reprieve Cardiovascular is .

  • How much funding has Reprieve Cardiovascular raised over time?

    Reprieve Cardiovascular has raised $103M.

  • Who are Reprieve Cardiovascular’s investors?

    Cadence Capital, Genesis Capital (Investment Banks), Santen Ventures, UNC Health Ventures, and Abiomed are 5 of 11 investors who have invested in Reprieve Cardiovascular.

  • Who are Reprieve Cardiovascular’s competitors?

    DexCom, Sensible Medical, Cardiac Dimensions, Spine Wave, and BrioHealth Solutions are some of the 14 competitors of Reprieve Cardiovascular.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process